Artificial intelligence was a recurring theme throughout the AVBCC 2026 conference, reflecting the growing interest in how these technologies may reshape cancer care. Discussions focused on AI’s potential to streamline administrative tasks, improve access to clinical information, and support decision-making across the oncology continuum. While enthusiasm for these capabilities was evident, speakers also emphasized the importance of understanding the broader implications that may accompany widespread adoption.
One of the most promising applications of AI in oncology is its ability to reduce the administrative burden facing clinicians. As the volume and complexity of clinical data continue to grow, physicians are increasingly challenged to synthesize information from electronic health records, pathology reports, biomarker testing, imaging studies, treatment guidelines, and evolving clinical evidence. AI tools have the potential to help organize and surface relevant information more efficiently, allowing clinicians to spend less time navigating data and more time focusing on their patients.
Conference speakers also highlighted AI’s potential to enhance clinical decision support. By rapidly analyzing large amounts of information, AI may help identify relevant treatment options, recommend appropriate testing, and alert clinicians to important changes in a patient’s condition. The goal is not to replace clinical judgment but to provide physicians with timely insights that support more informed and confident decision-making.
At the same time, several presenters discussed important economic considerations that healthcare organizations should monitor as AI adoption expands. Improved documentation capabilities, for example, could influence coding and reimbursement patterns. In addition, AI-generated recommendations or findings may lead to increased diagnostic testing, specialist referrals, or treatment interventions. These possibilities were presented as potential consequences that warrant further evaluation rather than established outcomes.
For healthcare leaders, these discussions reinforce the need to assess AI not only through the lens of technological innovation but also through its impact on clinical workflows, resource utilization, and overall healthcare spending. The long-term value of AI will ultimately depend on whether it can improve efficiency and patient care while supporting sustainable healthcare delivery.
As a practicing oncologist, I believe AI’s greatest potential lies in its ability to augment clinical expertise rather than replace it. Technology can help us process information faster and identify patterns that might otherwise be overlooked, but the interpretation of those insights still requires clinical experience, patient context, and human judgment. The future of oncology will likely be defined by how effectively we combine advanced technologies with the expertise of the clinicians who use them.
The conversations at AVBCC 2026 reflected both excitement and caution. AI offers significant opportunities to improve how cancer care is delivered, but realizing those benefits will require thoughtful implementation, ongoing evaluation, and a clear understanding of both the clinical and financial implications. As the technology continues to evolve, maintaining a balance between innovation and responsible adoption will be essential to ensuring that AI delivers meaningful value for patients, providers, and health systems alike.